CERYVYN THERAPEUTICS LIMITED ADR
WKN: A2QEW7 | ISIN: US68386J2087 | Ticker-Symbol: UKJ2Siehe auch CERYVYN THERAPEUTICS LIMITED
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.08. | CERYVYN THERAPEUTICS LIMITED: Notification regarding unquoted securities - CYV | 1 | ASX | ||
| 27.07. | CERYVYN THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 17.07. | CERYVYN THERAPEUTICS LIMITED: Update to Executive Chair Remuneration Arrangements | - | ASX | ||
| 13.07. | CERYVYN THERAPEUTICS LIMITED: Notification of cessation of securities - CYV | - | ASX | ||
| 10.07. | CERYVYN THERAPEUTICS LIMITED: Change of Company's Constitution | - | ASX | ||
| CERYVYN THERAPEUTICS LIMITED ADR Aktie jetzt für 0€ handeln | |||||
| 08.07. | OPTHEA LIMITED: Change of Company Name, ASX Code and Registered Office | 1 | ASX | ||
| 03.07. | OPTHEA LIMITED: Results of EGM | - | ASX | ||
| 25.06. | OPTHEA LIMITED: Change of Director's Interest Notice - JL | - | ASX | ||
| 25.06. | OPTHEA LIMITED: Notification regarding unquoted securities - OPT | - | ASX | ||
| 24.06. | OPTHEA LIMITED: Becoming a substantial holder | - | ASX | ||
| 22.06. | OPTHEA LIMITED: Ceasing to be a substantial holder | - | ASX | ||
| 19.06. | OPTHEA LIMITED: Change of Director's Interest Notice - KC & LG | - | ASX | ||
| 18.06. | Dr Boreham's Crucible: Opthea seeks a second act with rare lung disease program | 1 | Stockhead | ||
| 18.06. | OPTHEA LIMITED: Ceasing to be a substantial holder | - | ASX | ||
| 18.06. | OPTHEA LIMITED: Ceasing to be a substantial holder | - | ASX | ||
| 16.06. | OPTHEA LIMITED: Change in substantial holding | - | ASX | ||
| 12.06. | OPTHEA LIMITED: Change in substantial holding | - | ASX | ||
| 12.06. | OPTHEA LIMITED: Revised Webinar Details and Investor Presentation | - | ASX | ||
| 12.06. | OPTHEA LIMITED: Becoming a substantial holder | - | ASX | ||
| 10.06. | OPTHEA LIMITED: Change in substantial holding | - | ASX |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 10,500 | +0,19 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 4,430 | 0,00 % | COSCIENS Biopharma Inc. Reports Q2 2026 Results | TORONTO, ONTARIO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCI.F) ("COSCIENS" or the "Company") today reported its financial and operating results for the second... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 90,62 | -0,33 % | Halozyme: Mit fremden Blockbustern zum eigenen Wachstum | Was wäre, wenn man am Erfolg der nächsten Blockbuster partizipieren könnte, ohne die Risiken zu tragen? Halozyme könnte diese Möglichkeit bieten Den vollständigen Artikel lesen ... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 9,790 | 0,00 % | AbCellera-Aktie mit +18% - neues Allzeithoch möglich? | Die AbCellera-Aktie hat zuletzt erneut einen kräftigen Kurssprung hingelegt. Am gestrigen Handelstag ging es um +17,81% nach oben. Damit setzt sich die außergewöhnliche Rallye fort: Seit dem lokalen... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 334,00 | -0,24 % | ROUNDUP/'WSJ': US-Investor Elliot steigt bei Sartorius-Großaktionär Bio-Rad ein | NEW YORK (dpa-AFX) - Der US-Investor Elliott hat laut einem Medienbericht eine beachtliche Beteiligung an dem Sartorius-Großaktionär Bio-Rad Laboratories aufgebaut. Der aktivistische Investor wolle... ► Artikel lesen | |
| GLOW LIFETECH | 0,030 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Reports Positive Q2 2026 Results; Revenue Growth Continues for 12th Consecutive Quarter | Toronto, Ontario--(Newsfile Corp. - August 25, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the second... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy | Company expands team, university partnerships, and internship programs to build long-term biologics talent pipeline.TUSTIN, Calif., May 18, 2026 /PRNewswire/ -- Avid Bioservices, a leading... ► Artikel lesen | |
| BIOLINERX | 2,140 | +3,88 % | BioLineRx Q2 Earnings Preview | ||
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals: $1.3 Billion Financing Supports Radius Health Combination To Build Specialty Pharma Platform | ||
| MINERVA NEUROSCIENCES | 4,306 | -5,69 % | Minerva Neurosciences, Inc: Minerva Neurosciences to Participate in Two Upcoming Investor Conferences | BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 4,200 | 0,00 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights | Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026
Cash, cash equivalents and short-term... ► Artikel lesen | |
| OVID THERAPEUTICS | 2,480 | +3,33 % | Ovid Therapeutics Inc.: Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results | First-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 studyInitiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitorA... ► Artikel lesen | |
| COCRYSTAL | 0,980 | +1,55 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors | BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| INNOVENT BIOLOGICS | 11,640 | -1,56 % | Innovent Biologics: Innovent Announces 2026 Interim Results and Business Updates | Transforming from Regional Leader to Global Premier:
A Clear Strategic Path for Growth and Globalization
SAN FRANCISCO and SUZHOU, China, Aug. 25, 2026 /PRNewswire/... ► Artikel lesen | |
| GEOVAX LABS | 0,720 | -0,14 % | EQS-News: GeoVax, Inc.: GeoVax Announces a Warrant Inducement Transaction | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
GeoVax Announces a Warrant Inducement Transaction 26.08.2026 / 14:34 CET/CEST
The issuer is solely responsible for the content... ► Artikel lesen |
Das Unternehmen CERYVYN THERAPEUTICS LIMITED ADR kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERYVYN THERAPEUTICS LIMITED ADR finden Sie auf Wallstreet Online.